Kodiak Sciences Inc

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California, that develops therapies for retinal vascular diseases using its proprietary antibody–biopolymer conjugate (ABC) platform to extend intraocular durability and reduce treatment frequency; its lead candidate, KSI-301, is an anti‑VEGF ABC being evaluated in multiple clinical trials for indications such as wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion, and the company’s business activity centers on advancing that pipeline through clinical development and regulatory processes with the goal of commercializing new ophthalmic medicines.